• Publications
  • Influence
Dynamics of fat cell turnover in humans
Obesity is increasing in an epidemic manner in most countries and constitutes a public health problem by enhancing the risk for cardiovascular disease and metabolic disorders such as type 2 diabetes.Expand
  • 1,807
  • 78
  • PDF
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1
Gene transfer into hematopoietic stem cells has been used successfully for correcting lymphoid but not myeloid immunodeficiencies. Here we report on two adults who received gene therapy afterExpand
  • 1,098
  • 39
  • PDF
Inhibition of proteasome deubiquitinating activity as a new cancer therapy
Ubiquitin-tagged substrates are degraded by the 26S proteasome, which is a multisubunit complex comprising a proteolytic 20S core particle capped by 19S regulatory particles. The approval ofExpand
  • 302
  • 15
Fetal Mesenchymal Stem-Cell Engraftment in Bone after In Utero Transplantation in a Patient with Severe Osteogenesis Imperfecta
Background. Mesenchymal stem cells (MSC) are progenitors of mesenchymal tissues such as bone, cartilage, and adipose. Adult human leukocyte antigen (HLA)-matched MSC have been used in cellularExpand
  • 431
  • 7
Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.
PURPOSE A high degree of interindividual variation in cyclophosphamide (CPA) pharmacokinetics was reported in certain cancer patient groups. To better understand the mechanisms underlying theExpand
  • 100
  • 6
Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes
Several-fold differences have been observed among patients in the biotransformation of cyclophosphamide. The aim of this study was to investigate the contribution of CYP2C9 and CYP2C19 and theirExpand
  • 66
  • 4
Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology
SummaryBusulphan levels in plasma were measured in 27 patients during conditioning therapy (1 mg/kg×4 for 4 days) before bone marrow transplantation. The mean minimal concentration found in childrenExpand
  • 107
  • 3
Simple Method Based on Fluorescent Detection for the Determination of 4-Hydroxycyclophosphamide in Plasma
Cyclophosphamide is a prodrug used both as a single drug and in combination chemotherapy. Cyclophosphamide is converted to its active metabolite (4-hydroxycyclophosphamide) by the cytochrome P450Expand
  • 19
  • 3
Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics
The pharmacokinetics of high-dose busulphan was studied in 17 patients during conditioning prior to bone marrow transplantation using deuterium-labeled busulphan (d8-BU). About 50% of busulphan dosesExpand
  • 91
  • 2
Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients
Malär R, Sjöö F, Rentsch K, Hassan M, Güngör T. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients.
Pediatr TransplantationExpand
  • 68
  • 2